e-ISSN: Pending
Negative / Null Result ReportOpen accessNeurology. Diseases of the nervous system

Phosphatidylserine enriched with polyunsaturated n‐3 fatty acid supplementation for attention‐deficit hyperactivity disorder in children and adolescents with epilepsy: A randomized placebo‐controlled trial

Sylvain Rheims; Vania Herbillon; Ségolène Gaillard; Catherine Mercier; Nathalie Villeuve; Frédéric Villéga; Claude Cances; Pierre Castelnau · 2024 · Epilepsia Open

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract

Abstract Background Attention‐deficit hyperactivity disorder (ADHD) is a frequent comorbidity in children with epilepsy, which management mostly relies on the usual treatments of ADHD, especially methylphenidate. Supplementation with polyunsaturated n‐3 Fatty Acid (PUFA) has been proposed as an alternative therapeutic approach in ADHD without epilepsy but has never been evaluated in epilepsy‐associated ADHD. Methods A multicenter double blind randomized placebo‐controlled trial evaluating supplementation with PUFA, in eicosapentaenoic‐ and docosahexaenoic‐acid form, conjugated to a phospholipi

Abstract by Sylvain Rheims; Vania Herbillon; Ségolène Gaillard; Catherine Mercier; Nathalie Villeuve; Frédéric Villéga; Claude Cances; Pierre Castelnau, Epilepsia Open (2024) — licensed CC BY 4.0.

About to run something similar?

Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.

WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.

Metadata source: DOAJ · DOI 10.1002/epi4.12892